{"id":"NCT02638103","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine","officialTitle":"A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-02-26","primaryCompletion":"2018-06-06","completion":"2018-12-08","firstPosted":"2015-12-22","resultsPosted":"2019-08-28","lastUpdate":"2021-11-09"},"enrollment":1890,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"Fremanezumab","otherNames":["TEV-48125"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"TEV-48125 225 mg Monthly: New/Placebo Rollover Participants","type":"EXPERIMENTAL"},{"label":"TEV-48125 225 mg Monthly: Active Rollover Participants","type":"EXPERIMENTAL"},{"label":"TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants","type":"EXPERIMENTAL"},{"label":"TEV-48125 675 mg Quarterly: Active Rollover Participants","type":"EXPERIMENTAL"}],"summary":"A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous (SC) administration of TEV-48125 in adult participants with chronic migraine (CM) or episodic migraine (EM). Participants with CM or EM who complete the pivotal efficacy studies of TEV-48125 (TV48125-CNS-30049 \\[NCT02621931\\] and TV48125-CNS-30050 \\[NCT02629861\\]) and agree to participate in this study; and new participants meeting eligibility criteria (not rolling over from pivotal studies), will be enrolled in this study.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs)","timeFrame":"Baseline (Day 0) up to follow-up visit (Day 533)","effectByArm":[{"arm":"TEV-48125 225 mg Monthly: New/Placebo Rollover Participants","deltaMin":365,"sd":null},{"arm":"TEV-48125 225 mg Monthly: Active Rollover Participants","deltaMin":456,"sd":null},{"arm":"TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants","deltaMin":365,"sd":null},{"arm":"TEV-48125 675 mg Quarterly: Active Rollover Participants","deltaMin":426,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":12},"locations":{"siteCount":139,"countries":["United States","Canada","Czechia","Finland","Israel","Japan","Poland","Russia","Spain"]},"refs":{"pmids":["32913018","32887548"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":27,"n":418},"commonTop":["Injection site induration","Injection site pain","Injection site erythema","Upper respiratory tract infection","Nasopharyngitis"]}}